<DOC>
	<DOCNO>NCT01324505</DOCNO>
	<brief_summary>This clinical trial conduct Europe . The purpose trial investigate influence pharmacokinetics ( rate trial drug eliminate body ) oral contraceptive combination drug multiple administration semaglutide female subject type 2 diabetes .</brief_summary>
	<brief_title>Effect Oral Contraceptives After Administration Semaglutide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Informed consent obtain physician trialrelated activity Postmenopausal woman : . With least 12 month spontaneous amenorrhoea serum follicle stimulate hormone ( FSH ) 40 mIU/mL oestrogen deficiency ( estradiol level less 30 pg/mL , negative gestagen test ) b . Bilateral oophorectomy ( surgical removal ovary ) Type 2 diabetes treat either diet exercise alone metformin ( monotherapy ) glycosylated haemoglobin ( HbA1c ) 6.5 10 % ( inclusive ) Stable treatment diabetes , either diet exercise stable dose level metformin , least 3 month BMI ( Body Mass Index ) 18.5 35.0 kg/m^2 ( inclusive ) Known suspect hypersensitivity trial product relate product Previous participation trial . Participation define dosed either drug Treatment antidiabetic drug metformin within last 3 month Use hormone replacement therapy within 4 week prior start dose trial product Presence history cancer clinically significant disease disorder , consider physician influence result trial Subjects know hepatitis Positive human immunodeficiency virus ( HIV ) antibodies Uncontrolled treated/untreated hypertension ( systolic blood pressure 160 mmHg and/or diastolic blood pressure 100 mmHg ) History alcoholism drug abuse last 3 month History chronic idiopathic acute pancreatitis Family personal history multiple endocrine neoplasia type 2 ( MEN2 ) , family history medullary thyroid cancer ( FMTC ) Personal history nonfamilial medullary thyroid carcinoma Subjects consider increase risk thrombosis formation , deep vein thrombosis , pulmonary embolism , infarction apoplexy ( judge trial physician ) subject smoker Blood plasma donation within last 3 month prior first dose Participation trial investigating product involve blood sample within last 3 month prior first dose Inability unwillingness perform selfinjection ( placebo medium ) trial start</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>